Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | FKBP1A | P62942 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6791730 | 1.00 | NR1H2 (0.36) | NR1H2CYP3A4KDM4ECHRM1MAPT | |
| SCHEMBL6605366 | 0.91 | CYP3A4 (0.34) | CYP3A4KDM4ECHRM1MAPTTSHR | |
| SCHEMBL6324214 | 0.89 | CYP3A4 (0.34) | CYP3A4KDM4ECHRM1MAPTTSHR | |
| SCHEMBL6609747 | 0.89 | FKBP1A (0.33) | CYP3A4KDM4ECHRM1MAPTTSHR | |
| SCHEMBL6608201 | 0.88 | CYP3A4 (0.34) | CYP3A4KDM4ECHRM1MAPTTSHR | |
| SCHEMBL6605342 | 0.87 | CYP3A4 (0.33) | CYP3A4KDM4ECHRM1MAPTTSHR | |
| SCHEMBL6606308 | 0.86 | CYP3A4 (0.33) | CYP3A4KDM4ECHRM1MAPTTSHR | |
| SCHEMBL6608741 | 0.85 | CHRM1 (0.32) | CYP3A4KDM4ECHRM1MAPTCHRM5 | |
| SCHEMBL3305700 | 0.85 | CYP3A4 (0.44) | CYP3A4KDM4EMAPTTSHRFKBP1A | |
| SCHEMBL6326567 | 0.85 | NR1H2 (0.40) | NR1H2CYP3A4KDM4EMAPTTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6953805-B2 | Excitatory amino acid receptor antagonists | ELI LILLY AND COMPANY (US) | 2005-10-11 | — | — | US | disclosed |
| US-20050170999-A1 | EXCITATORY AMINO ACID RECEPTOR ANTAGONISTS | FILLA SANDRA A (US) | 2005-08-04 | — | — | US | disclosed |
| US-6855725-B2 | Excitatory amino acid receptor antagonists | ELI LILLY AND COMPANY (US) | 2005-02-15 | — | — | US | disclosed |
| US-20040063749-A1 | Excitatory amino acid receptor antagonists | BLEISCH THOMAS JOHN (US) | 2004-04-01 | — | — | US | disclosed |
| EP-0590789-B9 | Excitatory amino acid receptor antagonists | LILLY CO ELI (US) | 2004-02-04 | — | — | EP | disclosed |
| EP-1351951-A2 | PYRROLIDINYLMETHYL- AND PIPERIDINYL SUBSTITUTED DECAHYDROISOQUINOLINES AS EXCITATORY AMINO ACID RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2003-10-15 | — | — | EP | disclosed |
| EP-1351952-A2 | PYRROLIDINYLMETHYL SUBSTITUTED DECAHYDROISOQUINOLINES AS EXCITATORY AMINO ACID RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2003-10-15 | — | — | EP | disclosed |
| WO-2003082856-A1 | ISOQUINOLINE-3-CARBOXYLIC ACID DERIVATIVES AS EXCITATORY AMINO ACID RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2003-10-09 | — | — | WO | disclosed |
| EP-0590789-B1 | Excitatory amino acid receptor antagonists | LILLY CO ELI (US) | 2003-03-12 | — | — | EP | disclosed |
| WO-2002053556-A2 | PYRROLIDINYLMETHYL SUBSTITUTED DECAHYDROISOQUINOLINES AS EXCITATORY AMINO ACID RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2002-07-11 | — | — | WO | disclosed |
| US-5675008-A | Excitatory amino acid receptor antagonists | ELI LILLY AND COMPANY (US) | 1997-10-07 | — | — | US | disclosed |
| US-5670516-A | NERVOUS SYSTEM DISORDERS | ELI LILLY AND COMPANY (US) | 1997-09-23 | — | — | US | disclosed |
| US-5648492-A | Process for preparing isoquinoline compounds | ELI LILLY AND COMPANY (US) | 1997-07-15 | — | — | US | disclosed |
| US-5637712-A | CATALYTIC HYDROGENNATION | ELI LILLY AND COMPANY (US) | 1997-06-10 | — | — | US | disclosed |
| US-5606062-A | STEREOSELECTIVE REDUCTION | ELI LILLY AND COMPANY (US) | 1997-02-25 | — | — | US | disclosed |
| US-5527810-A | USEFUL IN THE TREATMENT OF NEUROLOGICAL DISORDERS | ELI LILLY AND COMPANY (US) | 1996-06-18 | — | — | US | disclosed |
| US-5399696-A | Excitatory amino acid receptor antagonists; nervous system disorders | ELI LILLY AND COMPANY (US) | 1995-03-21 | — | — | US | disclosed |
| US-5356902-A | Central nervous system disorders | ELI LILLY AND COMPANY (US) | 1994-10-18 | — | — | US | disclosed |
| EP-0590789-A1 | Excitatory amino acid receptor antagonists | ELI LILLY AND COMPANY (US) | 1994-04-06 | — | — | EP | disclosed |
| US-5284957-A | Substituted 1H- or 2H-tetrazoles | ELI LILLY AND COMPANY (US) | 1994-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050170999-A1 | EXCITATORY AMINO ACID RECEPTOR ANTAGONISTS | SLC1A2, SLC1A1, SLC1A3 | NR1H2 863/4885CYP3A4 3320/4885KDM4E 2406/4885 |
| US-20040063749-A1 | Excitatory amino acid receptor antagonists | SLC1A2, SLC1A1, SLC1A3 | NR1H2 890/4885CYP3A4 2826/4885KDM4E 1583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.